KRAS and pancreatic neoplasm: Some additional potential biomarkers that have been evaluated in pancreatic cancer treatment include deoxycytidine kinase (dCK), ribonucleoside reductase-M1 (RRM1), and -M2 (RRM2) [123,124], KRAS status, SPARC staining [58], IGF-1R expression, and rs9582036 single nucleotide polymorphism (SNP) in the VEGF receptor-1 region [125].